Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 179698, 7 pages
http://dx.doi.org/10.1155/2014/179698
Research Article

Fragile Histidine Triad (FHIT) Suppresses Proliferation and Promotes Apoptosis in Cholangiocarcinoma Cells by Blocking PI3K-Akt Pathway

1Department of General Surgery, Qilu Hospital of Shandong University, No. 107 Wenhuaxi Road, Jinan 250012, China
2Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, Hefei, Anhui 230001, China
3Hepatic-Biliary-Pancreatic Key Laboratory of Anhui Province, Hefei, Anhui 230001, China

Received 2 January 2014; Accepted 17 February 2014; Published 16 March 2014

Academic Editors: G. Bocci and G. Vecchio

Copyright © 2014 Qiang Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Friman, “Cholangiocarcinoma—current treatment options,” Scandinavian Journal of Surgery, vol. 100, no. 1, pp. 30–34, 2011. View at Google Scholar · View at Scopus
  2. D. K. Mishra, Z. Chen, Y. Wu, M. Sarkissyan, H. P. Koeffler, and J. V. Vadgama, “Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 33–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Vaiphei, A. Rangan, and R. Singh, “Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma,” World Journal of Gastrointestinal Oncology, vol. 4, no. 12, pp. 250–258, 2012. View at Publisher · View at Google Scholar
  4. D. T. Yin, L. Wang, J. Sun et al., “Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 5, pp. 482–491, 2010. View at Google Scholar · View at Scopus
  5. D. T. Yin, L. Wang, J. Sun et al., “Homozygous deletion but not mutation of exons 5 and 8 of the Fragile Histidine Triad (FHIT) gene is associated with features of differentiated thyroid carcinoma,” Annals of Clinical & Laboratory Science, vol. 40, no. 3, pp. 267–272, 2010. View at Google Scholar · View at Scopus
  6. Q. Huang, F. Xie, Z. Tang et al., “FHIT promotes the apoptosis of QBC939 by reducing the expression of cyclin D1,” Hepato-Gastroenterology, vol. 58, no. 107-108, pp. 713–718, 2011. View at Google Scholar · View at Scopus
  7. C. C. Lin, J. P. Zhou, Y. P. Liu et al., “The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway,” PLoS ONE, vol. 7, no. 12, Article ID e51916, 2012. View at Publisher · View at Google Scholar
  8. K. J. Schmitz, H. Lang, J. Wohlschlaeger et al., “AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma,” World Journal of Gastroenterology, vol. 13, no. 48, pp. 6470–6477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ohta, H. Inoue, M. G. Cotticelli et al., “The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma associated translocation breakpoint, is abnormal in digestive tract cancer,” Cell, vol. 84, no. 4, pp. 587–597, 1996. View at Google Scholar
  10. I. Romero, M. Martinez, C. Garrido et al., “The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells,” The Journal of Pathology, vol. 227, no. 3, pp. 367–379, 2012. View at Publisher · View at Google Scholar
  11. O. Wang, C. Y. Wang, J. Shi et al., “Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors,” Chinese Medical Journal, vol. 125, no. 16, pp. 2895–2901, 2012. View at Google Scholar
  12. V. K. Gopalakrishnan, A. G. Banerjee, and J. K. Vishwanatha, “Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells,” Pancreatology, vol. 3, no. 4, pp. 293–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Ottey, S. Y. Han, T. Druck et al., “Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant,” British Journal of Cancer, vol. 91, no. 9, pp. 1669–1677, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Shi, H. Zhang, M. Li et al., “Normal endometrial stromal cells regulate survival and apoptosis signaling through PI3K/AKt/Survivin pathway in endometrial adenocarcinoma cells in vitro,” Gynecologic Oncology, vol. 123, no. 2, pp. 387–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Q. Ye, W. Cai, Y. Zheng, B. M. Evers, and Q. B. She, “ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer,” Oncogene, 2013. View at Publisher · View at Google Scholar
  16. A. C. Mita, M. M. Mita, S. T. Nawrocki, and F. J. Giles, “Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics,” Clinical Cancer Research, vol. 14, no. 16, pp. 5000–5005, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Tang, Y. H. Lu, J. H. Xie et al., “Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis,” Anti-Cancer Drugs, vol. 20, no. 4, pp. 249–258, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Semba, F. Trapasso, M. Fabbri et al., “Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential,” Oncogene, vol. 25, no. 20, pp. 2860–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus